- ECONOMIC IMPACT -

Latest update: 29 June 

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022. 

The unemployment rate in OECD nations stood at 6.5% in March 2021, down from 6.6% in Feb 2021.

0.8%

According to the OECD, real GDP in the G20 area grew by 0.8% in Q1 2021 when compared to the last quarter and reached pre-pandemic level.

6.1%

The consensus global real GDP growth forecast for 2021 has been revised upward from the previous estimate of 4.9% to 6.1%.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 07 July

industry development

615

Starting at the end of May 2020, clinical trials in India increased dramatically. India passed Iran in the total number of Covid-19 trials in October and has now surpassed China with 615 trials currently underway.

75%

At its present rate of vaccination, the US will have been able to administer two doses of any vaccine to 75% of the entire population within 290 days, a time frame that is continually drawn out due to decreasing vaccination rates in adults.

Vaccine rollout

China has administered the most single doses of Covid-19 vaccines worldwide (1,185.78 million), followed by the US (323.32 million) and India (318.03 million). However, the US has lost its position in the top ten countries globally in the vaccination rate per 1,000 population.


Gibraltar has administered the most single doses of Covid-19 vaccine per 1,000 population worldwide, followed by the United Arab Emirates and the Seychelles.


Key pharma market developments

Share this article

Go to article: Home | Waive goodbye to vaccine patentsGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: DatwylerGo to article: Datwyler Company InsightGo to article: LabcorpGo to article: Biesterfeld Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Dr. Paul LohmannGo to article: ButterworthGo to article: SkyepharmaGo to article: BaxterGo to article: CommentGo to article: Speeding up patient access to innovative drugsGo to article: The competitive landscape of neoantigen-targeting therapeutics in oncologyGo to article: Bacterial “cell factories”: an eco-friendly approach to chemical productionGo to article: MDR set to transform how MedTech firms approach content managementGo to article: PerkinElmerGo to article: NiproGo to article: NiproGo to article: In DepthGo to article: Should UK children be vaccinated against chickenpox?Go to article: Fighting India’s ‘black fungus’ epidemicGo to article: What could a vaccine patent waiver mean for pharma manufacturing? Go to article: Algae proteins: a vision of the futureGo to article: A brief history of ALS awareness and its sparse treatments Go to article: Ferring draws closer to a microbiome breakthroughGo to article: The Solubility companyGo to article: Myonex Go to article: Owen MumfordGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue